261 related articles for article (PubMed ID: 25737012)
1. In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.
Ibáñez-Costa A; Gahete MD; Rivero-Cortés E; Rincón-Fernández D; Nelson R; Beltrán M; de la Riva A; Japón MA; Venegas-Moreno E; Gálvez MÁ; García-Arnés JA; Soto-Moreno A; Morgan J; Tsomaia N; Culler MD; Dieguez C; Castaño JP; Luque RM
Sci Rep; 2015 Mar; 5():8714. PubMed ID: 25737012
[TBL] [Abstract][Full Text] [Related]
2. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
[TBL] [Abstract][Full Text] [Related]
3. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
[TBL] [Abstract][Full Text] [Related]
4. Expression of ghrelin and ghrelin functional receptor GHSR1a in human pituitary adenomas.
Andrusiewicz M; Komarowska H; Skibińska I; Chmielewska M; Jaskuła-Świtek M; Liebert W; Waśko R; Kotwicka M
Pol Arch Intern Med; 2017 Mar; 127(3):163-169. PubMed ID: 28377557
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
[TBL] [Abstract][Full Text] [Related]
6. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
7. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.
Rincón-Fernández D; Culler MD; Tsomaia N; Moreno-Bueno G; Luque RM; Gahete MD; Castaño JP
Carcinogenesis; 2018 Mar; 39(3):447-457. PubMed ID: 29272342
[TBL] [Abstract][Full Text] [Related]
8. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.
Gahete MD; Córdoba-Chacón J; Hergueta-Redondo M; Martínez-Fuentes AJ; Kineman RD; Moreno-Bueno G; Luque RM; Castaño JP
PLoS One; 2011; 6(8):e23302. PubMed ID: 21829727
[TBL] [Abstract][Full Text] [Related]
9. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing of iodothyronine deiodinases in pituitary adenomas. Regulation by oncoprotein SF2/ASF.
Piekielko-Witkowska A; Kedzierska H; Poplawski P; Wojcicka A; Rybicka B; Maksymowicz M; Grajkowska W; Matyja E; Mandat T; Bonicki W; Nauman P
Biochim Biophys Acta; 2013 Jun; 1832(6):763-72. PubMed ID: 23462647
[TBL] [Abstract][Full Text] [Related]
11. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas.
Hashimoto K; Koga M; Motomura T; Kasayama S; Kouhara H; Ohnishi T; Arita N; Hayakawa T; Sato B; Kishimoto T
J Clin Endocrinol Metab; 1995 Oct; 80(10):2933-9. PubMed ID: 7559877
[TBL] [Abstract][Full Text] [Related]
12. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
Luque RM; Sampedro-Nuñez M; Gahete MD; Ramos-Levi A; Ibáñez-Costa A; Rivero-Cortés E; Serrano-Somavilla A; Adrados M; Culler MD; Castaño JP; Marazuela M
Oncotarget; 2015 Aug; 6(23):19619-33. PubMed ID: 26124083
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas.
Chaidarun SS; Klibanski A; Alexander JM
J Clin Endocrinol Metab; 1997 Apr; 82(4):1058-65. PubMed ID: 9100573
[TBL] [Abstract][Full Text] [Related]
14. The role of proto-oncogene GLI1 in pituitary adenoma formation and cell survival regulation.
Lampichler K; Ferrer P; Vila G; Lutz MI; Wolf F; Knosp E; Wagner L; Luger A; Baumgartner-Parzer S
Endocr Relat Cancer; 2015 Oct; 22(5):793-803. PubMed ID: 26219678
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy?
Beuschlein F; Hancke K; Petrick M; Göbel H; Honegger J; Reincke M
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):214-8. PubMed ID: 15891957
[TBL] [Abstract][Full Text] [Related]
16. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
Oyama K; Sanno N; Teramoto A; Osamura RY
Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
[TBL] [Abstract][Full Text] [Related]
17. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas.
Onguru O; Scheithauer BW; Kovacs K; Vidal S; Jin L; Zhang S; Ruebel KH; Lloyd RV
Mod Pathol; 2004 Jul; 17(7):772-80. PubMed ID: 15098012
[TBL] [Abstract][Full Text] [Related]
18. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
20. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
